[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1012288A1 - Oral liquid compositions containing paroxetine resinate - Google Patents

Oral liquid compositions containing paroxetine resinate

Info

Publication number
HK1012288A1
HK1012288A1 HK98113631A HK98113631A HK1012288A1 HK 1012288 A1 HK1012288 A1 HK 1012288A1 HK 98113631 A HK98113631 A HK 98113631A HK 98113631 A HK98113631 A HK 98113631A HK 1012288 A1 HK1012288 A1 HK 1012288A1
Authority
HK
Hong Kong
Prior art keywords
resinate
compositions containing
oral liquid
liquid compositions
containing paroxetine
Prior art date
Application number
HK98113631A
Other languages
English (en)
Inventor
Graham Stanley Leonard
David Cooper
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of HK1012288A1 publication Critical patent/HK1012288A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK98113631A 1994-02-03 1998-12-16 Oral liquid compositions containing paroxetine resinate HK1012288A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9402029A GB9402029D0 (en) 1994-02-03 1994-02-03 Novel formulation
PCT/EP1995/000319 WO1995020964A1 (en) 1994-02-03 1995-01-30 Oral liquid compositions containing paroxetine resinate

Publications (1)

Publication Number Publication Date
HK1012288A1 true HK1012288A1 (en) 1999-07-30

Family

ID=10749765

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98113631A HK1012288A1 (en) 1994-02-03 1998-12-16 Oral liquid compositions containing paroxetine resinate

Country Status (34)

Country Link
US (1) US5811436A (no)
EP (1) EP0742715B1 (no)
JP (1) JP4445590B2 (no)
CN (1) CN1074922C (no)
AP (2) AP611A (no)
AT (1) ATE178489T1 (no)
AU (1) AU682091B2 (no)
BG (1) BG62843B1 (no)
BR (1) BR9507055A (no)
CA (1) CA2182593A1 (no)
CZ (1) CZ285128B6 (no)
DE (1) DE69508924T2 (no)
DK (1) DK0742715T3 (no)
DZ (1) DZ1850A1 (no)
ES (1) ES2129806T3 (no)
FI (1) FI118205B (no)
GB (1) GB9402029D0 (no)
GR (1) GR3030131T3 (no)
HK (1) HK1012288A1 (no)
HU (1) HUT75941A (no)
IL (1) IL112521A (no)
MA (1) MA23441A1 (no)
MX (1) MX9603203A (no)
MY (1) MY113036A (no)
NO (1) NO307954B1 (no)
NZ (1) NZ278891A (no)
OA (1) OA10446A (no)
PL (1) PL178331B1 (no)
RO (1) RO116342B1 (no)
RU (1) RU2136281C1 (no)
SK (1) SK281214B6 (no)
TW (1) TW436296B (no)
WO (1) WO1995020964A1 (no)
ZA (1) ZA95776B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
JP2002503248A (ja) 1997-06-10 2002-01-29 シントン・ベスローテン・フェンノートシャップ 4−フェニルピペリジン化合物
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
EP1250937B1 (en) * 2001-04-09 2009-05-13 Rohm And Haas Company Controlled dissolution of active ingredients
US20020176842A1 (en) * 2001-04-09 2002-11-28 Lyn Hughes Extended release of active ingredients
US6906206B2 (en) * 2001-04-30 2005-06-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
GB0119467D0 (en) * 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
EP1414408B1 (en) * 2001-08-09 2006-03-29 Smithkline Beecham Plc Composition comprising paroxetine and a pharmaceutically acceptable glycyrrhizinate salt
US6939877B2 (en) * 2002-09-12 2005-09-06 Wyeth Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
EP1778183B1 (en) * 2004-08-18 2018-06-27 Synthon B.V. Liquid paroxetine compositions
EP1791531A1 (en) * 2004-08-20 2007-06-06 Alpharma, Inc. Paroxetine formulations
KR100672184B1 (ko) * 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
AU2006315684A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
CN102430122A (zh) * 2005-12-13 2012-05-02 量子高科(北京)研究院有限公司 盐酸氟西汀口腔崩解片及其制备方法
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20100273822A1 (en) * 2009-04-22 2010-10-28 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins
CA2765635C (en) * 2009-06-25 2016-09-06 Wockhardt Research Centre Pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof
US8187617B2 (en) * 2009-09-11 2012-05-29 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments
KR20130093010A (ko) 2010-05-19 2013-08-21 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 함유 의약 조성물
CN104027306A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 帕罗西汀口服混悬液及其制备方法
GB201419261D0 (en) 2014-10-29 2014-12-10 Therakind Ltd Formulations
CN104382870A (zh) * 2014-10-30 2015-03-04 万全万特制药江苏有限公司 一种含有波拉克林钾-帕罗西汀的复合物
CN106309363A (zh) * 2016-09-24 2017-01-11 万特制药(海南)有限公司 盐酸帕罗西汀口服混悬液及其制备方法
CN108926528A (zh) * 2017-05-25 2018-12-04 北京万全德众医药生物技术有限公司 含有氨磺必利树脂酸盐的口服液体组合物
JP2022523742A (ja) 2019-02-01 2022-04-26 ユニヴァーシティー オブ サウスカロライナ 二環式ピリジン組成物およびがんの治療にそれを使用する方法
CN113209017B (zh) * 2021-06-02 2023-06-20 上海美优制药有限公司 一种盐酸帕罗西汀混悬剂及其制备方法
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB9005498D0 (en) * 1990-03-12 1990-05-09 Beecham Group Plc Composition
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.

Also Published As

Publication number Publication date
FI963051A (fi) 1996-08-01
MY113036A (en) 2001-11-30
AP9600839A0 (en) 1996-07-31
CZ285128B6 (cs) 1999-05-12
SK100496A3 (en) 1996-12-04
CZ229396A3 (en) 1997-01-15
PL315679A1 (en) 1996-11-25
SK281214B6 (sk) 2001-01-18
ZA95776B (en) 1996-08-01
PL178331B1 (pl) 2000-04-28
FI118205B (fi) 2007-08-31
BG62843B1 (bg) 2000-09-29
CN1140411A (zh) 1997-01-15
RU2136281C1 (ru) 1999-09-10
EP0742715B1 (en) 1999-04-07
DE69508924T2 (de) 1999-10-21
IL112521A0 (en) 1995-05-26
GB9402029D0 (en) 1994-03-30
DK0742715T3 (da) 1999-10-18
AU1536895A (en) 1995-08-21
BG100763A (bg) 1997-03-31
ATE178489T1 (de) 1999-04-15
CN1074922C (zh) 2001-11-21
AP9500715A0 (en) 1995-04-30
JP4445590B2 (ja) 2010-04-07
MA23441A1 (fr) 1995-10-01
AU682091B2 (en) 1997-09-18
HU9602151D0 (en) 1996-09-30
CA2182593A1 (en) 1995-08-10
WO1995020964A1 (en) 1995-08-10
NO307954B1 (no) 2000-06-26
IL112521A (en) 1999-09-22
JPH09508402A (ja) 1997-08-26
DE69508924D1 (de) 1999-05-12
HUT75941A (en) 1997-05-28
DZ1850A1 (fr) 2002-02-17
OA10446A (en) 2002-03-26
BR9507055A (pt) 1997-09-02
AP536A (en) 1996-09-26
FI963051A0 (fi) 1996-08-01
RO116342B1 (ro) 2001-01-30
NO963244D0 (no) 1996-08-02
NZ278891A (en) 1998-01-26
GR3030131T3 (en) 1999-07-30
ES2129806T3 (es) 1999-06-16
MX9603203A (es) 1997-03-29
EP0742715A1 (en) 1996-11-20
NO963244L (no) 1996-08-02
TW436296B (en) 2001-05-28
AP611A (en) 1997-09-03
US5811436A (en) 1998-09-22

Similar Documents

Publication Publication Date Title
HU9602151D0 (en) Oral liquid compositions containing paroxetine resinate
ZA957980B (en) Oral compositions
PL322136A1 (en) Oral compositions
HU9601978D0 (en) Oral composition
AU2372095A (en) Oral compositions
GB9513694D0 (en) Oral compositions
GB9425934D0 (en) Oral compositions
GB9412048D0 (en) Oral hygiene composition
ZA955519B (en) Oral compositions
GB9515597D0 (en) Oral compositions
PL320866A1 (en) Oral compositions
HU9500618D0 (en) Oral pharmaceutical compositions
GB2307640B (en) Oral hygiene composition
PL321282A1 (en) Oral compositions
HUP9801706A3 (en) Oral compositions
IL139596A0 (en) Novel formulation containing paroxetine
PL320865A1 (en) Oral compositions
SI0742715T1 (en) Oral liquid compositions containing paroxetine resinate
IL139594A0 (en) Novel formulation containing paroxetine
GB2285923B (en) Pharmaceutical compositions containing N-acetal-cysteine
GB9510328D0 (en) Compositions containing zirconium compounds
GB9417357D0 (en) Dental compositions
IL107417A0 (en) Liquid dental compositions
GB9510391D0 (en) Oral compositions
GB9513693D0 (en) Oral compositions

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)